There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on United Therapeutics (UTHR) and Castle Biosciences (CSTL) with bullish sentiments.
United Therapeutics (UTHR)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on United Therapeutics, with a price target of $255.00. The company’s shares closed last Thursday at $167.26, close to its 52-week high of $171.17.
According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 24.2% and a 62.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for United Therapeutics with a $173.67 average price target.
See today’s analyst top recommended stocks >>
Castle Biosciences (CSTL)
Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences today and set a price target of $80.00. The company’s shares closed last Thursday at $75.62, close to its 52-week high of $80.12.
According to TipRanks.com, Souda is a 5-star analyst with an average return of 43.8% and a 85.3% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Twist Bioscience, and Guardant Health.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $77.50 average price target, representing a 3.3% upside. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $80.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
